share_log

MAIA Biotechnology To Present Late-Breaking THIO-101 Phase 2 Trial Updates On THIO And Cemiplimab Combo In NSCLC At SITC 2024, Highlighting Long-Term Therapeutic Benefits Beyond Treatment Cessation

Benzinga ·  Nov 5 22:49
MAIA Biotechnology To Present Late-Breaking THIO-101 Phase 2 Trial Updates On THIO And Cemiplimab Combo In NSCLC At SITC 2024, Highlighting Long-Term Therapeutic Benefits Beyond Treatment Cessation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment